337 related articles for article (PubMed ID: 9737840)
1. The cost of treating community-acquired pneumonia.
Niederman MS; McCombs JS; Unger AN; Kumar A; Popovian R
Clin Ther; 1998; 20(4):820-37. PubMed ID: 9737840
[TBL] [Abstract][Full Text] [Related]
2. Treatment cost of acute exacerbations of chronic bronchitis.
Niederman MS; McCombs JS; Unger AN; Kumar A; Popovian R
Clin Ther; 1999 Mar; 21(3):576-91. PubMed ID: 10321424
[TBL] [Abstract][Full Text] [Related]
3. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
4. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
5. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis.
Rozenbaum MH; Mangen MJ; Huijts SM; van der Werf TS; Postma MJ
Vaccine; 2015 Jun; 33(28):3193-9. PubMed ID: 25981488
[TBL] [Abstract][Full Text] [Related]
6. CAPECO: Cost evaluation of community acquired pneumonia managed in primary care.
Personne V; Chevalier J; Buffel du Vaure C; Partouche H; Gilberg S; de Pouvourville G
Vaccine; 2016 Apr; 34(19):2275-80. PubMed ID: 26979138
[TBL] [Abstract][Full Text] [Related]
7. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
8. Treatment costs of community-acquired pneumonia in an employed population.
Colice GL; Morley MA; Asche C; Birnbaum HG
Chest; 2004 Jun; 125(6):2140-5. PubMed ID: 15189934
[TBL] [Abstract][Full Text] [Related]
9. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years.
Sato R; Gomez Rey G; Nelson S; Pinsky B
Appl Health Econ Health Policy; 2013 Jun; 11(3):251-8. PubMed ID: 23605251
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population.
Yu H; Rubin J; Dunning S; Li S; Sato R
J Am Geriatr Soc; 2012 Nov; 60(11):2137-43. PubMed ID: 23110409
[TBL] [Abstract][Full Text] [Related]
11. Hospitalized low-risk community-acquired pneumonia: outcome and potential for cost-savings.
Hoe LK; Keang LT
Respirology; 1999 Sep; 4(3):307-9. PubMed ID: 10489681
[TBL] [Abstract][Full Text] [Related]
12. Diabetes mellitus and infection: an evaluation of hospital utilization and management costs in the United States.
Korbel L; Spencer JD
J Diabetes Complications; 2015 Mar; 29(2):192-5. PubMed ID: 25488325
[TBL] [Abstract][Full Text] [Related]
13. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital.
Goss CH; Rubenfeld GD; Park DR; Sherbin VL; Goodman MS; Root RK
Chest; 2003 Dec; 124(6):2148-55. PubMed ID: 14665494
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study.
McLaughlin JM; Johnson MH; Kagan SA; Baer SL
Infection; 2015 Dec; 43(6):671-80. PubMed ID: 25980561
[TBL] [Abstract][Full Text] [Related]
15. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.
Coyne KS; Paramore C; Grandy S; Mercader M; Reynolds M; Zimetbaum P
Value Health; 2006; 9(5):348-56. PubMed ID: 16961553
[TBL] [Abstract][Full Text] [Related]
16. Community-acquired pneumonia: the annual cost to the National Health Service in the UK.
Guest JF; Morris A
Eur Respir J; 1997 Jul; 10(7):1530-4. PubMed ID: 9230242
[TBL] [Abstract][Full Text] [Related]
17. Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity.
Cupurdija V; Lazic Z; Petrovic M; Mojsilovic S; Cekerevac I; Rancic N; Jakovljevic M
J Bras Pneumol; 2015; 41(1):48-57. PubMed ID: 25750674
[TBL] [Abstract][Full Text] [Related]
18. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines.
Orrick JJ; Segal R; Johns TE; Russell W; Wang F; Yin DD
Pharmacoeconomics; 2004; 22(11):751-7. PubMed ID: 15250752
[TBL] [Abstract][Full Text] [Related]
19. The annual economic burden among patients hospitalized for community-acquired pneumonia (CAP): a retrospective US cohort study.
Divino V; Schranz J; Early M; Shah H; Jiang M; DeKoven M
Curr Med Res Opin; 2020 Jan; 36(1):151-160. PubMed ID: 31566005
[No Abstract] [Full Text] [Related]
20. Costs of treating lower respiratory tract infections.
Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
